iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
ACH-3102 (NS5A) + Ribavirin
  ACH-3102 and Ribavirin in Genotype-1b Hepatitis C Patients: Confirmation of the High Barrier to Viral Breakthrough in Genotype-1b HCV......
A Single Direct-acting Anti-viral Agent, ACH-3102, with Ribavirin is Able to Achieve a Robust Anti-viral Response in Subjects with Genotype 1b Chronic Hepatitis C Infection......
Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat Hepatitis C Virus......
Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen......
EASL: ACH-3422, a Novel Nucleotide Prodrug Inhibitor of HCV NS5B Polymerase - monotherapy study in patients- (04/31/15)
EASL: Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: a Phase 2 "Proxy" Study - (04/31/15)
New HCV Drugs new nukes-NS5A/Protease
APASL: SVR4 Results for the Combination of ACH-3102 and Sovaprevir, With Ribavirin, in Patients With Genotype 1 Chronic Hepatitis C Infection - (04/17/14)

  iconpaperstack View Older Articles   Back to Top   www.natap.org